Premium
Emerging Target‐Based Paradigms to Prevent and Treat Migraine
Author(s) -
Silberstein S D
Publication year - 2013
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2012.198
Subject(s) - migraine , calcitonin gene related peptide , medicine , clinical pharmacology , calcitonin , pharmacology , receptor , cortical spreading depression , chronic migraine , neuroscience , bioinformatics , psychology , neuropeptide , biology
Migraine is a primary brain disorder resulting from altered modulation of normal sensory stimuli and trigeminal nerve dysfunction. The second edition of the International Classification of Headache Disorders (ICHD‐2) defines seven subtypes of migraine. Migraine treatment can be acute or preventive. New targeted therapies include 5‐HT 1F receptor agonists, calcitonin gene‐related peptide (CGRP) antagonists, nitric oxide synthetase inhibitors, and ion channel antagonists. A recent development is the creation of antibodies to CGRP and its receptor for migraine prevention. Clinical Pharmacology & Therapeutics (2013); 93 1, 78–85. doi: 10.1038/clpt.2012.198